Peters C, Bruno A, Rizzari C, Brescianini A, von Stackelberg A, Linderkamp C, Zeng Y, Zugmaier G, Locatelli F. Blinatumomab is associated with better post-transplant outcome than chemotherapy in children with high-risk, first-relapse B-cell acute lymphoblastic leukemia irrespective of the conditioning regimen. Haematologica 2025;110(1):234-238; https://doi.org/10.3324/haematol.2024.285837.